ArticlePulmonary circulation2026
Prognostic Value of Acute Vasoreactivity in Chronic Thromboembolic Pulmonary Hypertension.
Article in Pulmonary circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pulmonary vascular reactivity in severe pulmonary hypertension associated with COPD.ERJ open research · 2026Article
- Prognostic Value of Acute Vasoreactivity in Chronic Thromboembolic Pulmonary Hypertension.Pulmonary circulation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vasoreactivity, which refers to the reduction of mean pulmonary arterial pressure in response to inhaled vasodilators, is a well-established metric for prognostication and treatment selection in patients with pulmonary arterial hypertension. However, the role of vasoreactivity in chronic thromboembolic pulmonary hypertension is less studied. We investigated whether vasoreactivity at time of diagnosis carries prognostic value in all patients with chronic thromboembolic pulmonary hypertension, and how it relates to the effect of long-term pulmonary vasodilator treatments. Patients diagnosed with CTEPH were prospectively subjected to 40 ppm inhaled nitric oxide testing at the diagnostic right heart catheterization. Classic (acute decrease of mean pulmonary arterial pressure > 10 mmHg to a level below 40 mmHg,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.